Company Overview
Snapshot
Founded in April 2014 by Itschak Lamensdorf, Nachshol Cohen, and Yoram Sela, Alvit LCS Pharma operates with 1–10 employees. In October 2018, the company secured a manufacturing and licensing agreement with Bazelet, Israel's largest medical cannabis company, to produce and distribute its pharmaceutical-grade medical cannabis products in Israel and the EU.
Business overview
Alvit LCS Pharma is a vertically integrated medical cannabis research and development company focused on pharmaceutical-grade cannabis product development and drug-delivery technologies. The company's product portfolio includes various tablets, sprays, and suppositories. Alvit manages the entire cannabis drug-development lifecycle, from Good Agriculture Practice-controlled cultivation of proprietary cannabis clones and standardized extracts to preclinical evaluations, proprietary formulations, and first-in-human studies. It serves the healthcare and life sciences sectors, specifically targeting the pharmaceuticals market with its medical cannabis solutions.
Strategic signal
In January 2019, Alvit LCS Pharma sponsored the Cannabis Pavilion at Davos, where its CEO presented the company's commitment to fostering key relationships and showcasing its products and technologies. This event highlighted the company's strategic focus on establishing its presence and expertise in the global medical cannabis industry, signaling its intent to drive market adoption and physician understanding of pharmaceutical-grade cannabis.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant strategic partnership for Alvit LCS Pharma?
- In October 2018, Alvit LCS Pharma signed a manufacturing and licensing agreement with Bazelet, Israel's largest medical cannabis company. This partnership enables Bazelet to manufacture, market, and sell Alvit's pharmaceutical-grade medical cannabis products in Israel and the EU. They also agreed to collaborate on research and development for a new pharmaceutical drug to treat Inflammatory Bowel Disease (IBD).
- What was Alvit LCS Pharma's involvement at Davos?
- In January 2019, Alvit LCS Pharma sponsored the Cannatechs Canada Cannabis House in Davos. The company's CEO presented at the event, emphasizing Alvit's dedication to building key relationships and demonstrating its products and technologies, particularly its pharma-grade products and drug delivery systems.
- What was the focus of Alvit LCS Pharma's merger activity in 2018?
- In November 2018, Alvit LCS Pharma announced the merger of its cannabis growing operations into Intelicann, an Israeli cannabis cultivation facility publicly traded on the Tel Aviv Stock Exchange.
- What is Alvit LCS Pharma's approach to cannabis drug development?
- Alvit LCS Pharma controls the entire lifecycle of cannabis drug development. This includes Good Agriculture Practice-controlled cultivation of proprietary cannabis clones, standardized extracts, preclinical evaluations, proprietary formulations, and first-in-human studies.
- What types of products does Alvit LCS Pharma develop?
- Alvit LCS Pharma develops pharmaceutical-grade cannabis products, including various types of tablets, sprays, and suppositories, utilizing advanced drug-delivery technologies.